FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
SI0848705T1
(en)
|
1995-07-17 |
2002-04-30 |
Warner-Lambert Company |
Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
|
US6569461B1
(en)
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
IN191236B
(da)
|
1999-05-25 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
ES2349364T3
(es)
*
|
1999-11-17 |
2010-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Procedimiento para la preparación de una forma polimórfica de atorvastatina cálcica.
|
SI20425A
(sl)
|
1999-12-10 |
2001-06-30 |
LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. |
Priprava amorfnega atorvastatina
|
ES2252088T3
(es)
|
1999-12-17 |
2006-05-16 |
Pfizer Science And Technology Ireland Limited |
Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina.
|
AU780247B2
(en)
*
|
1999-12-17 |
2005-03-10 |
Pfizer Science And Technology Ireland Limited |
A process for producing crystalline atorvastatin calcium
|
EP1332130A4
(en)
*
|
2000-11-03 |
2004-01-21 |
Teva Pharma |
HEMICALCIC ATORVASTATIN FORM VII
|
IL156055A0
(en)
*
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
LT5196B
(lt)
|
2000-11-30 |
2005-02-25 |
Teva Pharmaceutical Industries Ltd. |
Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
HUP0302519A3
(en)
|
2000-12-27 |
2008-10-28 |
Teva Pharma |
Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
EP1724256A3
(en)
|
2001-01-09 |
2007-03-21 |
Warner-Lambert Company LLC |
Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
*
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
UA74075C2
(en)
*
|
2001-06-29 |
2005-10-17 |
Warner Lambert Co |
NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
|
JP2005500351A
(ja)
*
|
2001-07-30 |
2005-01-06 |
ドクター・レディーズ・ラボラトリーズ・リミテッド |
結晶形態viおよびviiのアトルバスタチンカルシウム
|
US7074818B2
(en)
|
2001-07-30 |
2006-07-11 |
Dr. Reddy's Laboratories Limited |
Crystalline forms VI and VII of Atorvastatin calcium
|
PE20030324A1
(es)
*
|
2001-07-31 |
2003-04-03 |
Warner Lambert Co |
Composiciones farmaceuticas de amlodipina y atorvastatina
|
ES2304140T3
(es)
*
|
2001-08-03 |
2008-09-16 |
Ciba Holding Inc. |
Formas cristalinas de sodio de fluvastatina.
|
US20060020137A1
(en)
*
|
2001-11-29 |
2006-01-26 |
Limor Tessler |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
CZ296967B6
(cs)
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
EP1480950A4
(en)
*
|
2002-02-15 |
2005-05-18 |
Teva Pharma |
NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX
|
CA2475123A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Teva Pharmaceutical Industries Ltd. |
Desolvating solvates of atorvastatin hemi-calcium
|
CZ2004943A3
(cs)
*
|
2002-03-18 |
2005-02-16 |
Biocon Limited |
Amorfní HMG-CoA inhibitory obsahující reduktázu s požadovanou velikostí částic
|
ITMI20020907A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
|
RS20050105A
(en)
*
|
2002-08-06 |
2007-11-15 |
Warner-Lambert Company Llc., |
Process for preparing 5-(4-(54) fluorophenyl)-1-(2-((2r,4r)-4- hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl)- 2-isopropyl-4- phenyl-1h-pyrrole-3- carboxylic acid phenylamide
|
CA2491051A1
(en)
*
|
2002-09-03 |
2004-03-18 |
Morepen Laboratories Limited |
Atorvastatin calcium form vi or hydrates thereof
|
SI21302A
(sl)
|
2002-10-11 |
2004-04-30 |
LEK farmacevtska dru�ba d.d. |
Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
|
HRP20020885B1
(en)
*
|
2002-11-11 |
2007-05-31 |
GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. |
SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
|
EP1572643A2
(en)
*
|
2002-11-28 |
2005-09-14 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form f of atorvastatin hemi-calcium salt
|
EP1424324A1
(en)
*
|
2002-11-28 |
2004-06-02 |
Teva Pharmaceutical Industries Limited |
Crystalline form F of Atorvastatin hemi-calcium salt
|
RS20050760A
(sr)
*
|
2003-04-14 |
2008-04-04 |
Warner-Lambert Company Llc., |
Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
CN101318923A
(zh)
*
|
2003-09-17 |
2008-12-10 |
沃尼尔·朗伯有限责任公司 |
[R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸的结晶形式
|
MXPA06011987A
(es)
*
|
2004-04-16 |
2007-01-16 |
Pfizer Prod Inc |
Procedimiento para formar calcio de atorvastatina amorfa.
|
ES2739493T3
(es)
|
2004-05-05 |
2020-01-31 |
Pfizer Prod Inc |
Formas de sal de de atorvastatina con benetamina
|
AU2005263550C1
(en)
*
|
2004-07-16 |
2013-01-17 |
Lek Pharmaceuticals D.D. |
Oxidative degradation products of atorvastatin calcium
|
EP1771412A2
(en)
|
2004-07-20 |
2007-04-11 |
Warner-Lambert Company LLC |
Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
|
JP2008510798A
(ja)
|
2004-08-27 |
2008-04-10 |
バイオコン・リミテッド |
非晶質アトルバスタチンカルシウムのための方法
|
TWI321132B
(en)
|
2004-09-28 |
2010-03-01 |
Teva Pharma |
Process for preparing forms of atorvastatin calcium substantially free of impurities
|
MX2007004425A
(es)
|
2004-10-18 |
2007-06-07 |
Teva Pharma |
Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
|
CN101048141A
(zh)
|
2004-10-28 |
2007-10-03 |
沃尼尔·朗伯有限责任公司 |
形成非晶形的阿托伐他汀的方法
|
WO2006048894A1
(en)
*
|
2004-11-05 |
2006-05-11 |
Morepen Laboratories Limited |
Novel crystalline forms of atorvastatin calcium and processes for preparing them.
|
AU2005305460B2
(en)
|
2004-11-22 |
2011-04-21 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
JP2008521878A
(ja)
*
|
2004-12-02 |
2008-06-26 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
非晶質アトルバスタチンの医薬組成物及びその製造のための方法
|
GB2424880A
(en)
*
|
2005-04-06 |
2006-10-11 |
Generics |
Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
|
CA2547216A1
(en)
*
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
US8084488B2
(en)
*
|
2005-11-21 |
2011-12-27 |
Pfizer Inc. |
Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
|
TW200745026A
(en)
|
2005-12-13 |
2007-12-16 |
Teva Pharma |
Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
|
EP1810667A1
(en)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmaceutical composition comprising amorphous atorvastatin
|
EP1877375A1
(en)
*
|
2006-03-01 |
2008-01-16 |
Teva Pharmaceutical Industries Ltd |
Process for preparing a crystalline form of atorvastatin hemi-calcium
|
US20070265456A1
(en)
*
|
2006-05-09 |
2007-11-15 |
Judith Aronhime |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
KR100878140B1
(ko)
*
|
2007-01-29 |
2009-01-12 |
한미약품 주식회사 |
아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
|
US20100260851A1
(en)
*
|
2007-07-11 |
2010-10-14 |
Actavis Group Ptc Ehf |
Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
|
WO2009013633A2
(en)
*
|
2007-07-20 |
2009-01-29 |
Actavis Group Ptc Ehf |
Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
|
DE102007052071A1
(de)
|
2007-10-30 |
2009-05-07 |
Stada Arzneimittel Ag |
Stabilisiertes Atorvastatin
|
US20090124817A1
(en)
*
|
2007-11-09 |
2009-05-14 |
The Industry & Academic Cooperation In Chungnam National University |
Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
|
US8115015B2
(en)
*
|
2009-01-26 |
2012-02-14 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
CZ201039A3
(cs)
|
2010-01-19 |
2011-07-27 |
Zentiva, K. S |
Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
|
KR20120011249A
(ko)
*
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
CN103274985B
(zh)
*
|
2010-12-03 |
2016-03-09 |
上海科州药物研发有限公司 |
一种阿托伐他汀氨基酸盐
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
CN103702982A
(zh)
*
|
2011-07-01 |
2014-04-02 |
中化帝斯曼制药有限公司荷兰公司 |
阿托伐他汀半钙的超细晶体
|
CN103483238B
(zh)
*
|
2013-08-20 |
2014-12-31 |
蚌埠丰原医药科技发展有限公司 |
阿托伐他汀钙三水合物的制备方法
|
CN106432033B
(zh)
*
|
2016-10-21 |
2018-07-27 |
江苏阿尔法药业有限公司 |
一种无定形阿托伐他汀钙的制备方法
|
KR101723783B1
(ko)
|
2017-02-24 |
2017-04-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|